Note: Descriptions are shown in the official language in which they were submitted.
CA 02645398 2008-11-13
PURIFICATION OF BIOLOGICAL SUBSTANCES
This is a division of copending Canadian Patent Application Serial No.
2,361,545 with a national
phase entry date of July 19, 2001 based on PCT/US00/40035 filed February 22,
2000.
BACKGROUND OF THE INVENTION
Field of the Invention
The invention relates generally to a method and apparatus for purifying target
biological substance(s), such as selected proteins, antibodies, antigens,
clotting factors,
glycoproteins, and hormones, from source liquids containing contaminants that
have
molecular weights or other physical or chemical properties that differ from
those of the
target substance, wherein the purification is effected by sequential
chromatographic and
diafiltration separation steps in a cross-flow filtration system.
Description of the Related Art
Various methods of purification have been employed for the separation of
substances from liquid samples. Precipitation, centrifugation, filtration,
chromatography
and evaporation have all been employed with varying success with respect to
yield, time
consumption, purity and cost.
In the area of biological purification, centrifugation, chromatography and
filtration
have been especially useful for obtaining highly valuables substances from
liquid samples
with yields ranging from 10 to 90 percent and purity as high as 95 percent.
In current applications of centrifugation, chromatography and filtration, it
is
generally understood that yield and purity are in an inverse relationship and
that yields are
significantly lower for each subsequent purification step. It is also well
understood that
these methods of centrifugation, chromatography and filtration are expensive,
relatively
slow, and employ equipment that is very difficult to clean prior to its reuse.
A particular problem in this respect is the cleaning of fixed bed
chromatography
columns, in which irregular flow channels tend to be formed through the
chromatography
resin. These irregular flow channels present a particular problem in the
purification of
1
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
biological substances, since a failure to completely clean the column can
result in the
contamination of subsequent batches.
An example is the. purification of plasma proteins on ion exchange and
affinity
chromatography columns. If a batch of plasma tested to be free of virus is
later learned to
be contaminated with virus, it is nearly impossible to calculate the certainty
of removal of
the virus from the column. In addition, because biological liquids readily
support the
growth of bacteria, simple bacterial contamination and growth of organisms in
chromatographic columns is by no means infrequent. Bacterial organisms and the
endotoxins produced by the bacteria have contaminated countless batches of
pharmaceutical products resulting in significant financial losses as well as
adverse
reactions in the recipients of the final product.
The frequently observed "rat tunnels" which present so many problems for
validation of the cleaning process also negate a significant portion of the
capacity and
resolution capability of chromatography columns.
Another problem of fixed bed chromatography columns is compression of the
resin,
particularly in the case of softer gels such as agarose (e.g., Sepharose gel,
commercially
available from Pharmacia). The joint problems of tunneling and compression
significantly
raise the cost of chromatography by necessitating large amounts of excess
binding
capacity. Another problem caused by compression and tunneling is loss of
purity. High
purity requires uniform elution of the target substance. Tunneling and
compression prevent
uniform distribution of the elution liquid, resulting in imprecise separation
of the target
substance from contaminants which have similar el.ution profiles to the target
product as
well as to randomly eluted contaminants entrapped in the compressed media.
In the case of monoclonal antibody purification, it is a common practice to
pack a
column with a ten-fold excess binding capacity. In a well-distributed system
it would be
possible to bind the entire target product with only a three-fold excess
capacity, thereby
reducing the cost of the chromatography media three-fold.
2
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
One conunon approach to decreasing tunneling and conipression is to lower the
operating pressure of the column by reducing the flow rate. Although the
practice of
reducing the flow rate decreases the compression of the resin, it
significantly increases the
processing time and in many cases adversely effects the resolution and the
yield of the
process.
Tangential flow filtration utilizes membranes of various pore sizes for
separating
substances in liquids by pumping the liquid parallel to the membrane surface.
Although
this process has proven effective in the concentration of substances suspended
in water
and/or buffers, it has not proven widely useful in the purification of
compounds in solution.
The first problem of this method is that the pore size is not sufficiently
uniform to allow for
the separation of two closely sized particles. In addition, substances in the
liquid mixture,
especially proteins and lipids, bind to the surface of the membrane, a
phenomenon referred
to as "gel layer polarization," changing the effective pore size as well as
the surface
chemistry of the membrane.
Fluidized bed chromatography is another means of separating substances from
liquid mixtures. Fluidized bed chromatography is more commonly utilized in the
chemical
and petroleum industries. Fluidized bed columns are frequently 10 feet high or
higher and
9 to 12 inches in diameter. Pharmaceutical and bioprocess columns are usually
less than 3
feet high and have a wide variety of diameters in the general range of from 1
to 24 inches,
depending on the compression characteristics of the resin. The advantages of a
fluidized
bed are higher flow rates at lower pressures as compared to fixed bed
chromatography.
Although the higher flow rates offer certain advantages to the chromatographic
separation,
the method has several shortcomings. The method requires larger diameter
resins that are
neutral to gravity or buoyant. These larger, 100 to 300 micron mean diameter
resins have
less surface area per unit volume than smaller, 1 to 100 micron resins used in
fixed bed
columns, and correspondingly have less surface binding capacity.
To minimize the loss of surface area and decrease density, the fluidized bed
resins
are highly porous structures. These resin particles, however, as a result of
their porous,..
character, are highly susceptible to cracking, thereby generating small
particulates that
block the inlet and outlet ports of the column.
3
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
The most significant problem of the fluidized bed is mixing. Since the column
does
not contain any static mixing means, the bed is conventionally mixed by means
of air jets
or by recycling the liquid to be separated through the column at a high flow
rate. The high
flow rate and limited mixing inhibit the uniform phase change required during
elution of
the product from the resin.
As a result of the above-described deficiencies in the art, there is a
compelling need
for a rapid, uniform, time- and cost-efficient system for purifying biological
target
substances from complex liquid sources. Such a system would desirably overcome
the
problems inherent in the various prior art separation technologies described
above. Such a
system also would desirably be readily scalable, being adaptable to process
volumes of
source material ranging from milliliters in the research laboratory to the
thousands of liters
commonly encountered in biopharmaceutical production. Finally, such a system
would
desirably be capable of use with source liquids of widely varying properties,
including
viscous complex solutions.
SUMMARY OF THE INVENTION
The present invention relates to a purification method that employs one or
more
cross-flow filter elements and one or more types of chromatography resins, in
combination,
to provide purification with advanantageous yield, product purity, and cost-
and time-
efficiency.
The cross-flow filter module(s) used in the practice of the present invention
may be
of any suitable type, including for example cross flow filters such as hollow
fiber filters,
spiral filters, plate and frame filters, cassette filters, stir cells, tubular
filters, ceramic filters,
etc.
The method of the invention involves purifying target biological substance(s),
such
as for example selected proteins, antibodies, antigens, clotting factors,
glycoproteins, and
hormones, from source liquids containing contaminants that have molecular
weights or
4
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
other physical or chemical properties that differ from those of the target
substance, wherein
sequential chromatographic and diafiltration separation steps accomplished in
a cross-flow
filtration system.
The purification method of the invention provides high yields and rapid
isolation of
proteins, antibodies, growth hormones and other biologically significant
substances from
complex liquid sources, e.g., plasma, plasma fractions, milk, colostrum,
cheese whey, cell
culture and tissue culture fluids, and tissue and cell homogenates.
Further, the method of the invention may be applied to traditional
purification
methodologies to increase the yields of the traditional separations and to
render those
traditional methods suitably clean to allow for reuse and decontamination of
affinity and/or
filtration media as well as apparatus surfaces used in such purifications.
More specifically, the present invention in one aspect relates to a process
for
purifying a target substance from a source liquid, such process in one
embodiment
comprising the steps of:
1) contacting the source liquid with a chromatography resin;
2) incubating the source liquid with the chromatography resin for a sufficient
contact time
to allow the resin to bind a desired fraction of target substance;
3) recirculating the cluomatography resin in a cross-flow filter system
wherein the
following steps are performed:
a) concentrating the chromatography resin and separating contaminants from the
chromatography-resin-bound target substance by diafiltration;
b) eluting the target substance from the chromatography resin; and
c) separating the target substance from the chromatography resin by
diafiltration;
4) recovering the target substance; and
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
5) optionally concentrating the target substance.
The purification method may further comprise optional initial steps of (a)
clarification of the source liquid to remove any undesirable particulates that
are present and
that have the potential to clog pores or orifices in later steps, and (b)
concentration or
dilution of the source liquid such that the step of contacting the source
liquid with the
chromatography resin may proceed most efficiently. These steps are preferably
performed
by cross-flow filtration, with addition of a selected amount of liquid to the
system to yield
a clarified source liquid of desired concentration for use in the subsequent
incubation step.
The purification process of the present invention may further comprise added
steps
leading to isolation of additional target substance(s); in these added steps
the permeate
generated by the concentration and diafiltration of the chromatography resin,
prior to
elution, may be passed to a second chromatography resin or a series of
chromatography
resins and steps (1) - (4) are repeated. Alternatively, or additionally, the
purification
process of the present invention may further comprise repetition of steps (1) -
(4) applied
to diafiltrate from step 3(a) above, to increase the yield of target
substance.
The purification method may advantageously employ a chromatography resin
comprising rigid spherical cellulose beads with bound affinity ligands in the
chromatographic separation step(s).
The method of the invention in another aspect comprises a method for purifying
an
immunoglobulin from a source liquid, comprising the steps of contacting the
source liquid
with a chromatography resin, wherein the chromatography resin comprises
Protein A
linked to rigid, non-porous spherical beads;
incubating the source liquid with the chromatography resin for a sufficient
contact
time to allow the resin to bind a desired fraction of the immunoglobulin;
recirculating the chromatography resin in a cross-flow filter system wherein
the
following steps are performed:
6
CA 02645398 2008-11-13
WO 00/48703 PCT/USOO/40035
concentrating the chromatography resin and separating contaminants from
the chromatography-resin-bound immunoglobulin by diafiltration;
eluting the inununoglobulin from the chromatography resin;
recovering the immunoglobulin from the chromatography resin by
diafiltration; and
optionally concentrating the immunoglobulin.
In a further aspect, the present invention comprises a purification apparatus,
for
separating and concentrating a target substance from a source liquid, such
apparatus
comprising:
a first reservoir constructed and arranged for holding a solid-phase
chromatography
resin material, and for selectively flowing liquid into and out of said first
reservoir;
a solid-phase chromatography resin material disposed in said first reservoir;
a first cross-flow filtration module for separating liquids into permeate and
retentate
streams, provided with means for flowing liquid in and permeate and
retentate liquid streams out of said first cross-flow filtration module;
a second reservoir constructed and arranged for capturing and holding the
permeate
liquid stream, and for selectively flowing liquid into and out of said second
reservoir;
a second cross-flow filtration module for concentrating a liquid stream,
provided
with means for flowing liquid in and permeate and retentate liquid streams
out of said second cross-flow filtration module;
a collection vessel constructed and adapted for capturing the concentrated
liquid
stream from the second cross-flow filtration module; and
7
CA 02645398 2008-11-13
WO 00/48703 PCTIUS00/40035
conduit, valve and pump means constructed and arranged for:
providing make-up liquids to the first and second reservoirs;
selectively flowing a source liquid to the first reservoir charged with a
chromatography resin to form a slurry;
incubating the source liquid with the chromatography resin by recirculating
the slurry from the first reservoir to the first cross-flow filtration
module and returning both the permeate and retentate liquid streams
to the first reservoir;
recirculating the slurry in a cross-flow filter in a flow pathway adapted for:
concentrating the slurry and separating contaminants from the slurry
by diafiltration;
eluting the target substance from the chromatography resin; and
separating the target substance from the chromatography resin by
diafiltration;
capturing the target substance in the second reservoir;
concentrating the target substance by flowing it from the second reservoir
through the second cross-flow filtration module; and
recovering the concentrated target substance from the flow pathway of the
second cross-flow filtration module in the collection vessel.
In preferred embodiments of the apparatus, the first and second reservoirs are
provided with thermal jackets to maintain appropriate process temperatures.
8
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
In another aspect, the invention relates to a method of purification of a
liquid
containing a target substance, comprising the steps of contacting the liquid
with a
chromatography resin to bind the target substance thereto, and cross-flow
filtering the
target substance-bound chromatography resin under elution conditions to
recover a filtrate
comprising the target substance.
Such method may be carried out to effect a separation selected from. the group
consisting of:
separating the liquid to produce a vaccine or vaccine component;
separating plasma or a plasma fraction into its constituent parts;
separating clostrum into its constituent parts;
separating milk into its constituent parts;
separating whey into its constituent parts;
separating a fermentation fluid into its constituent parts;
separating insect cell culture fluid into its constituent parts;
separating viral culture fluid into its constituent parts;
separating an immunoglobulin from an immunoglobulin-containing culture of
bacteria, yeast, fungus, insect cells, or animal cells;
separating an immunoglobulin from serum;
separating an immunoglobulin from plasma or a plasma fraction;
separating an inununoglobulin from whole blood;
9
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
separating an immunoglobulin from milk;
separating an immunoglobulin from clostrum;
separating an inununoglobulin from whey;
separating an immunoglobulin from ascites fluid;
separating a clotting factor from whole blood;
separating a clotting factor from plasma;
separating a clotting factor from serum;
separating a clotting factor from a clotting factor-containing culture of
bacteria,
yeast, fungus, insect cells, or animal cells;
separating a clotting factor from milk;
separating a clotting factor from whey;
separating a clotting factor from clostrum;
separating a clotting factor from ascites fluid;
separating a protein from a protein-containing culture of bacteria, yeast,
fungus,
insect cells, or animal cells;
separating an antigen from an antigen-containing culture of bacteria, yeast,
fungus,
insect cells, or animal cells;
separating an antigen from a viral culture containing same;
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
separating a hormone from a hormone-containing culture of bacteria, yeast,
fungus,
insect cells, or animal cells;
separating a hormone from serum;
separating a hormone from plasma or a plasma fraction;
separating a hormone from whole blood;
separating a hormone from plasma;
separating a hormone from serum;
separating a hormone from milk;
separating a hormone from whey;
separating a hormone from clostrum;
separating a hormone from ascites fluid;
separating a hormone from tissue;
separating a glycoprotein from a viral culture;
separating a glycoprotein from a glycoprotein-containing culture of bacteria,
yeast,
fungus, insect cells, or animal cells;
separating a glycoprotein from serum;
separating a glycoprotein from plasma or a plasma fraction;
separating a glycoprotein from whole blood;
11
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
separating a glycoprotein from plasma;
separating a glycoprotein from serum;
separating a glycoprotein from milk;
separating a glycoprotein from whey;
separating a glycoprotein from clostrum;
separating a glycoprotein from ascites fluid; and
separating a glycoprotein from tissue.
A further aspect of the invention relates to a method of separating a liquid
in a
separation system comprising a bioreactor, a chromatographic resin reservoir,
a first cross-
flow filtration module, a second cross-flow filtration module, and a third
cross-flow
filtration module, such method comprising clarifying the perfusate of the
bioreactor in the
first cross-flow filtration module to yield a permeate, flowing the permeate
to the
chromatographic resin reservoir and flowing chromatographic resin and permeate
to the
second cross-flow filtration module for concentration, diafiltration and
elution to yield an
eluate, and flowing the eluate to the third cross-flow filtration module for
concentration
and diafiltration therein.
The invention in another aspect relates to a method of purifying at least one
target
substance from a source liquid containing a bioactive contaminant, comprising
the steps of:
contacting the source liquid with a chromatography resin;
12
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
incubating the source liquid with the chromatography resin for a sufficient
contact
time to bind to the chromatography resin at least one target substance from
the
source liquid;
recirculating the chromatography resin in a cross-flow filter wherein the
following
steps are performed:
concentrating the chromatography resin by diafiltration;
eluting the target substance from the chromatography resin; and
separating the target substance from the chromatography resin by
diafiltration;
recovering the target substance; and
optionally concentrating the target substance;
further comprising inactivating the bioactive contaminant during said method.
Another aspect of the invention relates to a process for purifying one or more
target
substances from a source liquid containing such target substances. The process
comprises:
contacting the source liquid with a chromatography resin;
recirculating the chromatography resin in at least one cross-flow filter
wherein the
following steps are performed:
concentrating the target substance and chromatography resin in the source
liquid by tangential flow filtration;
diafiltering the chromatography resin in a filter comprising a membrane
effective to retain the resin and pass species that are not bound to the
resin;
13
CA 02645398 2008-11-13
WO 00/48703 PCTIUSOO/40035
eluting the target substance from the chromatography resin by contact with
an elution membrane effective to retain the resin and pass the target
substance(s);
separating the target substance from the chromatography resin by diafiltration
recovering the target substance(s); and
optionally concentrating the target substance(s).
In another aspect, the invention relates to a process for purifying one or
more target
substances from a source liquid containing said target substances together
with one or more
viral species, such process comprising:
contacting the source liquid with a viral inactivation agent for the one or
more viral
species;
concentrating the target substance(s) in the source liquid by tangential flow
filtration in a tangential flow filter comprising a membrane effective to
concentrate at least
90% by weight of the target substance(s) in such filtration;
contacting the source liquid with a chromatography resin;
incubating the source liquid with the chromatography resin for a sufficient
contact
time to bind a desired fraction of the target substance(s);
recirculating the chromatography resin in a cross-flow filter wherein the
following
steps are performed:
concentrating the chromatography resin and separating contaminants from
the chromatography-resin-bound target substance by diafiltration in a filter
comprising a
membrane effective to retain the resin and pass species that are not bound to
the resin;
14
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
eluting the target substance from the chromatography resin by contact with
an elution membrane effective to retain the resin and pass the target
substance(s);
separating the target substance from the chromatography resin by
diafiltration;
recovering the target substance(s); and
optionally concentrating the target substance(s), e.g., by contact with a
concentration membrane effective to yield a concentrate comprising at least
90% by weight
target substance(s).
In another aspect, the present invention relates to a method of manufacturing
universal plasma from blood containing serological Group A and/or Group B
antibodies,
comprising contacting the blood containing serological Group A and/or Group B
antibodies with a chromatography resin comprising corresponding Group A and/or
Group
B antigen, and recovering an antibodies-depleted blood product as the
universal plasma.
Numerous other aspects, features and illustrative embodiments of the invention
will
be more fully apparent from the ensuing disclosure and appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a general scheme of a purification method according to one
embodiment of the invention, using a cross-flow filtration based apparatus.
Figure 2 shows a schematic representation of an apparatus useful for
clarifying a
source liquid to be submitted to subsequent purification steps.
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
Figure 3 shows the microscopic topography of an Orbicell bead used in a
chromatography resin, in comparison with that of a standard prior art porous
bead.
Figure 4 shows a schematic illustration of the flow pathways around an
Orbicell
bead, by comparison with the flow pathways around and through a standard prior
art
porous bead.
Figure 5 shows a schematic representation of an apparatus useful for carrying
out
the cross-flow chromatographic purification, elution, recovery and
concentration steps of
the method of the present invention, in one embodiment thereof, in which cross-
flow filter
module is employed.
Figure 6 shows a schematic representation of an alternative apparatus useful
for
carrying out the cross-flow chromatographic purification, elution, recovery
and
concentration steps of the method of the present invention, in another
embodiment thereof,
employing additionally a second cross-flow filter module of different porosity
than the
first.
Figure 7 shows an SDS polyacrylamide gel electrophoresis analysis of an IgG
sample purified from raw human plasma by the method of the present invention.
Figure 8 shows an SDS polyacrylamide gel electrophoresis analysis of an IgG
sample purified from cell culture media by the method of the present
invention.
DETAILED DESCRIPTION OF THE INVENTION, AND PREFERRED
EMBODIMENTS THEREOF
16
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
Definitions, Materials and Equipment
In the description of the present invention, certain terms are used as defined
below.
A "source liquid" as used herein refers to a liquid containing at least one
and
possibly two or more biological substances or products of value which are
sought to be
purified from other substances also present. In the practice of the invention,
source liquids
may for example be aqueous solutions, organic solvent systems, or
aqueous/organic
solvent mixtures or solutions. The source liquids are often complex mixtures
or solutions
containing many biological molecules such as proteins, antibodies, hormones,
and viruses
as well as small molecules such as salts, sugars, lipids, etc. While a typical
source liquid of
biological origin may begin as an aqueous solution or suspension, it may also
contain
organic solvents used in earlier separation steps such as solvent
precipitations, extractions,
and the like. Examples of source liquids that may contain valuable biological
substances
amenable to the purification method of the invention include, but are not
limited to, a
culture supematant from a bioreactor, a homogenized cell suspension, plasma,
plasma
fractions, milk, colostrum and cheese whey.
The term "target substance" refers herein to the one or more desired product
or
products to be purified from the source liquid. Target substances are
typically biological
products of value, for example, immunoglobulins, clotting factors, vaccines,
antigens,
antibodies, selected proteins or glycoproteins, peptides, enzymes, etc. The
target substance
may be present in the source liquid as a suspension or in solution. For
convenience, the
term "target substance" is used herein in the singular, but it should be
understood that it
may refer to more than one substance that is to be purified, either together
as co-products
or separately (e.g., sequentially) as discrete recovered components.
"Contaminants" refers to materials in the source liquid that are different
from the
target substance(s) and are desirably excluded from the final target substance
product(s).
Typical contaminants include nucleic acids, proteins, peptides, endotoxins,
viruses, etc.
Contaminants that can be removed by the practice of the inventive method have
one or
more properties that differ from those of the desired product, e.g., molecular
weight,
charge, specific affinity for various ligands, and so forth. Many contaminants
are
17
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
bioactive, and their removal is imperative for the purified product to be
usable in its end
application. Additionally, because of deleterious effects that they may exert
on the target
products in subsequent usages, certain contaminants must be cleaned from the
purification
apparatus to extremely low and preferably undetectable levels. The method of
the present
invention enables highly efficient decontamination, as will be described in
more detail
hereinafter.
"Cross-flow filter" refers herein to a type of filter module or filter
cassette that
comprises a porous filter element across a surface of which the liquid medium
to be filtered
is flowed in a tangential flow fashion, for permeation through the filter
element of selected
component(s) of the liquid medium. In a cross-flow filter, the shear force
exerted on the
filter element (separation membrane surface) by the flow of the liquid medium
serves to
oppose accumulation of solids on the surface of the filter element. Cross-flow
filters
include microfiltration, ultrafiltration, nanofiltration and reverse osmosis
filter systems.
The cross-flow filter may comprise a multiplicity of filter sheets (filtration
membranes) in
an operative stacked arrangement, e.g., wherein filter sheets alternate with
permeate and
retentate sheets, and as a liquid to be filtered flows across the filter
sheets, impermeate
species, e.g. solids or high-molecular-weight species of diameter larger than
the filter
sheet's pore size, are retained and enter the retentate flow, and the liquid
along with any
permeate species diffuse through the filter sheet and enter the permeate flow.
In the
practice of the present invention, cross-flow filtration is a preferred
separation method.
Cross-flow filter modules and cross-flow filter cassettes useful for such
filtration are
conunercially available from North Carolina SRT, Inc. (Cary, North Carolina).
Suitable
cross-flow filter modules and cassettes of such types are variously described
in the
following United States patents of the inventor of the present invention:
United States
Patent No. 4,867,876, "Filter Plate, Filter Plate Element, and Filter
Comprising Same,
issued September 19, 1989; United States Patent No. 4,882,050, same title,
issued
November 21, 1989; United States Patent No. 5,034,124, same title, issued
September 11,
1990; United States Patent No. 5,034,124, same title, issued July 23, 1991;
United States
Patent No. 5,049,268, same title, issued September 17, 1991; United States
Patent No.
5,232,589, "Filter Element and Support, issued August 3, 1993; United States
Patent No.
5,342,517, "Filter Cassette Article," issued August 30, 1994; United States
Patent No.
18
CA 02645398 2008-11-13
5,593,580, same title, issued January 14, 1997; and United States Patent No.
5,868,930,
same title, issued February 9, 1999.
"Chromatography resin" refers herein to a solid phase that selectively or
preferentially binds one or more components of the source liquid. In the
practice of the
invention, such "chromatography resins" can be selected from any of the groups
of resins
commonly described as affinity, ion exchange and ion capture resins. The
resins need only
possess a chemistry or an associated ligand that will selectively or
preferentially capture a
substance of interest from the source liquid. Useful chromatography resins
typically.
comprise a support and one or more ligand(s) bound thereto that provide(s) the
selective or
preferential binding capability for the target substance(s) of interest.
Useful supports
include, by way of illustrative example, polysaccharides such as agarose and
cellulose,
organic polymers such as po]yacrylamide, methylmethacrylate, and polystyrene-
divinylbenzene copolymers such as for example Amberlite resin, commercially
available
from Rohm & Haas Chemical Co., Philadelphia, PA. It should be recognized that
although
the term "resin" is conunonly used in the art of chromatography, it is not
intended herein to
imply that only organic substrates are suitable for resin substrate use, since
inorganic
support materials such as silica and glasses have utility as well. In the
practice of the
present invention, the resin may be in the form of beads which are generally
spherical, or
alternatively the resin may be usefully provide in particulate or divided
forms having other
regular shapes or irregular shapes. The resin may be of porous or nonporous
character, and
the resin may be compressible or incompressible. Preferred resins will be
physically and
chemically resilient to the conditions employed in the purification process
including
pumping and cross-flow filtration, and temperatures, pH, and other aspects of
the liquids
employed. The resin as employed in the practice of the present invention is
preferably of
regular generally spherical shape, nonporous and imcompressible.
"Affinity ligand" refers to a moiety that binds selectively or preferentially
to a
component of the source liquid through a specific interaction with a binding
site of the
component. In the practice of the invention, the affinity ligand is typically
immobilized to
a solid phase such as a resin. Examples of affinity ligands that can be bound
to the resin
19
CA 02645398 2008-11-13
WO 00/48703 PCTIUSOO/40035
support to provide chromatography resins useful in the process of the present
invention
include: protein A and protein A analogs, which selectively bind to
irnmunoglobulins;
dyes; antigens, useful for purification of associated antibodies; antibodies,
for purification
of antigens; substrates or substrate analogs, for purification of enzymes; and
the like.
Affinity ligands and methods of binding them to solid support materials are
well known in
the purification art. See, e.g., the reference texts Affinity Separations: A
Practical
Approach (Practical Approach Series), Paul Matejtschuk (Editor), Irl Pr: 1997;
and Affinity
Chromatography, Herbert Schott, Marcel Dekker, New York: 1997.
"Affinity chromatography resin" or "affinity resin" refers to a chromatography
resin that comprises a solid support or substrate with affinity ligands bound
to its surfaces.
Illustrative, non-limiting examples of suitable affinity chromatography resins
include
spherical beads with affinity ligands bound to the bead surfaces, wherein the
beads are
formed of cellulose, poly-styrene-divinylbenzene copolymer,
polymethylmethacrylate, or
other suitable material. In the practice of the present invention, rigid beads
that can
withstand pumping and recirculation through a cross-flow filtration module
while
maintaining structural integrity (e.g., without significant breakage
generating pore-
clogging particulates) are preferred. Particularly preferred are rigid, non-
porous cellulose
beads with bound affmity ligands. An illustrative particularly preferred
embodiment
employs "Orbicello" beads (commercially available from Accurate Polymers,
Inc.,
Highland Park, IL) that can be covalently coupled, e.g., by well-known methods
within the
skill of the art, to suitable affinity ligands, e.g. Protein A.
"Ion exchange chromatography resin" or "ion exchange resin" refers to a solid
support to which are covalently bound ligands that bear a positive or negative
charge, and
which thus has free counterions available for exchange with ions in a solution
with which
the ion exchange resin is contacted.
"Cation exchange resins" refers to an ion exchange resin with covalently bound
negatively charged ligands, and which thus has free cations for exchange with
cations in a
solution with which the resin is contacted. A wide variety of cation exchange
resins, for
example, those wherein the covalently bound groups are carboxylate or
sulfonate, are
known in the art. Commercially available cation exchange resins include CMC-
cellulose,
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
SP-Sephadex , and Fast S-Sepharose (the latter two being commercially
available from
Phannacia).
"Anion exchange resins" refers to an ion exchange resin with covalently bound
positively charged groups, such as quaternary amino groups. Commercially
available anion
exchange resins include DEAE cellulose, QAE Sephadex , and Fast Q Sepharose
(the
latter two being commercially available from Pharmacia).
"Dialysis liquid" or "dialysis buffer" or "diafiltrate" all refer herein to
the liquid
used in the diafiltration step to cany away contaminants from the target
substance-
chromagraphy resin complexes. Suitable dialysis liquids aid in the removal of
contaminants from the resin by acting to disrupt non-specific binding of
contaminants to
the chromatography resin without causing significant dissociation of the bound
target
substance from the resin. The dialysis liquid can be as simple as water or as
complex as
multicomponent solvent mixtures such as for example a solvent mixture
containing 80%
hexane, 15% acetonitrile and 5% isopropanol, wherein all percentages are by
volume,
based on the total volume of the mixture. More than one dialysis liquid may be
employed
sequentially, e.g., with the successive dialysis liquids having varying
properties such as pH
values, conductivity, solvent concentration, etc., designed to dissociate and
remove varying
types of contaminants that are non-specifically associated with the
chromatography resin.
An example of a dialysis liquid useful in the purification of selected
proteins such as
inununoglobulins is an aqueous buffered 0.4 M NaCI solution.
"Wash liquid" or "wash buffer" as used herein are synonymous with dialysis
liquid
or dialysis buffer, that is, liquids used to wash contaminants away from the
chromatography resin to which is bound the target substance.
"Elution liquid" or "elution buffer" refers herein to the liquid that is used
to
dissociate the target substance away from the chromatography resin after it
has been
cleansed of contaminants. The elution liquid acts to dissociate the target
substance without
denaturing it irreversibly. Typical elution liquids are well known in the
chromatography
art and may have higher concentrations of salts, free affinity ligands or
analogs, or other
substances that promote dissociation of the target substance from the
chromatography
21
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
resin. "Elution conditions" refers to process conditions imposed on the target
substance-
bound chromatography resin that dissociate the (undenatured) target substance
from the
chromatography resin, such as the contacting of the target substance-bound
chromatography resin with an elution liquid or elution buffer to produce such
dissociation.
"Cleaning liquid" or "cleaning buffer" refers herein to the liquid that is
used to
wash the chromatography resin after the completion of the purification
process. The
cleaning liquid may contain a detergent, a virus-inactivating agent, or
relatively high
concentrations of salts, and may have a higher or lower pH than the liquids
used during the
purification process. Its purpose is to fully decontaminate the chromatography
resin to
render it ready for reuse. Typical cleaning liquids are well-known in the
chromatography
art.
"Storage liquid" or "storage buffer" refers herein to the liquid in which the
chromatography resin is suspended between uses. Storage liquids, in addition
to buffering
ions, may also contain microbicides or other preservatives. Such storage
liquids are well
known in the chromatography art.
Purification Process
Figure 1 shows a general scheme that may be used to purify a target substance
in
the practice of the invention, as described in more detail below. Initially,
the source liquid
is optionally (a) clarified to remove potentially interfering particulates and
(b) concentrated
or diluted, as necessary for the subsequent purification steps. If the source
liquid is
sufficiently free of particulates and/or of an appropriate concentration in
its originally
supplied form, either or both of these steps (a) and (b) may be omitted.
The source liquid is then (1) transferred to a first reservoir where it is
contacted
with a chromatography resin, which selectively or preferentially binds the
target substance.
The source liquid is (2) incubated with the chromatography resin for a
sufficient contact
time to lead to binding of a desirably high percentage of the target substance
to the
chromatography resin, and to form resulting resin-target complexes. During the
incubation
the source liquid is stirred by an appropriate means, including cross-flow
filtration where
22
CA 02645398 2008-11-13
WO 00/48703 PCT/[JS00/40035
the permeate is recycled back to the reservoir, so that contact between the
resin and the
target substance is fully assured.
The resin is (3) recirculated through a cross-flow filter where (a) the resin
is
concentrated; (b) the resin is diafiltered against a first diafiltrate liquid
which is selected to
dissociate non-specifically binding components from the resin while not
disrupting the
resin-target complexes; (c) the substance of interest is eluted from the resin
by treatment
with a second diafiltration liquid which is selected to dissociate the
specific target-resin
complexes; (d) the target is diafiltered away from the resin. The diafiltrate
containing the
target substance is (4) captured in a second reservoir; and (5) the target
substance is
concentrated to a useful concentration.
The optional first clarification step is performed to remove from the source
liquid
particulate contaminants whose mean diameters are larger than the pore size of
the
separating cross-flow filter module used in the subsequent steps. This first
clarification
step, where required, avoids the concentration of particulate material in the
chromatography resin slurry, and it additionally prevents the particulate
contaminants from
dissolving during the later steps of the purification process and
contaminating the purified
target substance.
The clarification step can be accomplished by methods well-known in the
purification art, for example, centrifugation, gravity separation,
precipitation, flocculation-
assisted sedimentation, decanting, normal filtration, sieving, absorption,
adsorption and
tangential flow filtration. Altematively, the source liquid may already be
sufficiently clean
to make this step unnecessary.
Figure 2 shows a schematic flowsheet of a system 20 for clarification of a
source
liquid by cross-flow filtration and transfer of the clarified source liquid to
a reservoir for
subsequent purification steps. Refemng to Figure 2, the source liquid,
typically a
supematant or a suspension originating in a fermentor or bioreactor 21, is
carried via
conduit 22 to reservoir 23, which is provided with a thermal jacket 24 to keep
the source
liquid at a suitable temperature. Pump 28 is activated and the source liquid
is circulated
from reservoir 23 through cross-flow filter module 27 via conduits 24, 25, and
26, with
23
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
valves 30 and 32 in the closed position, and valve 31 optionally open to
return the retentate
to the reservoir 24 for additional filtration cycles. Make-up buffer is added
to reservoir 23
via conduit 29. Permeate (clarified source liquid) is carried via conduit 33
to a second
reservoir 34 where it is held for subsequent purification steps. Reservoir 34
is also
provided with a thermal jacket 35 to keep the clarified source liquid at an
appropriate
temperature. After use, when the system is to be purged and cleaned, valves 30
and 32 are
opened and conduits 36 and 37 carry wash liquid to suitable drain and/or
collection means.
The source liquid is then contacted with an appropriate chromatography resin,
in
reservoir 34 as depicted in Figure 2. It is possible to add the chromatography
resin to the
reservoir already containing the (optionally clarified) source liquid, or
alternatively the
chromatography resin may be charged to the reservoir and the source liquid
thereafter
added, or the contacting of the chromatography resin and the source liquid may
be carried
out in any other suitable manner, e.g., in a batch, semi-batch or continuous
manner.
Suitable chromatography resins for use in this step may be in the form of
beads or
other particulate or finely divided forms capable of binding the target
substance. The
beads are preferably sized with a diameter that is about 1.5 to 10 times
larger than the pore
size of the separating filter. The chromatography resin can be selected from
any of the
groups of resins commonly described as affinity, ion exchange and ion capture
resins, and
a wide variety of resins of such types is readily commercially available. The
resins possess
a chemistry or ligand chemistry that will capture the substance of interest
and bind the
target substance to the resin.
A particularly useful chromatography resin is provided in the form of
uniformly
spherical, non-porous, rigid, non-agglomerating, particles that are in the
range of about 0.1
to 1,000 microns in size and have a low affinity for nonspecific binding. In
one particularly
preferred embodiment of the invention, the chromatography resin comprises
cellulose
beads, 1 to 3 microns in diameter, with Protein A ligands covalently bound to
its surface.
Such beads are highly useful in the purification of monoclonal antibodies from
tissue
culture and mouse ascites fluid. Beads of such type are commercially available
under the
trademark "Orbicell " from Accurate Polymers, Inc. (Highland Park, Illinois).
24
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
Figure 3 depicts the surface and cross-section of such Orbicell beads 2,
showing
their high surface area but lack of interior porosity, as a result of which
such beads possess
high mechanical strength, as contrasted to standard porous beads 3. The high
strength and
rigidity of the Orbicell beads make them especially suitable for
recirculation through the
cross-flow filters, since they are not prone to breaking into smaller
particulates which can
clog filter pores and they are not prone to compressing and forming irregular
flow
pathways. Other types of beads of corresponding character to such Orbicell
beads are
commercially available and usefully employed in the practice of the present
invention.
Figure 4 schematically illustrates the simpler flow pathways present when
using the
Orbicell beads 4 as opposed to porous beads 5 of the type used in prior art
bioseparations.
Such prior art porous beads are less advantageous in their physical properties
with respect
to their resilience and resistance to breakage under extended pumping and
recirculation
conditions, than the non-porous beads preferably used in the practice of the
present
invention. An additional benefit of non-porous beads is that contaminants
would not be
entrapped in the pore only to elute out during the elution step lowering the
purity of the
target substance.
Referring now to Figure 5, the chromatography resin-source liquid slurry is
incubated for an appropriate contact time in reservoir 34 following the
initial processing
described hereinabove with reference to Figure 2. A simple method of
incubation may
entail stirring or shaking the reservoir 34 containing the slurry. In a
preferred embodiment
of the invention, the resin/liquid slurry is recirculated through line 36
under the action of
pump 38 and through line 40 (having drain line 47 containing valve 49
connected thereto)
across the separating cross-flow filter module 42, with the liquid being
recycled from the
filter module 42 through line 44 having backpressure valve 46 to the reservoir
34 at a
volumetric flow rate sufficient to keep filter 42 clean. Permeate is returned
to reservoir 34
through line 50 through open valve 58 through line 56 providing an appropriate
contact or
incubation time for the liquid in the reservoir.
The preferred contact (incubation) time in the reservoir 34 depends on the
particular
chromatography resin employed and its concentration of binding sites for the
target
substance, as well as the relative concentration of beads and target
substance. The reaction
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
time of the chemistry will vary from ligand to ligand, but the higher the
concentration of
available binding sites compared to the target substance, the shorter the
preferred
incubation time. It is contemplated that excess resin may be optimized in
various
applications at 1.2 to 10 fold higher concentration than the target substance.
A further
consideration in the optimization of the method is the concentration of the
resin suspended
in the liquid. Resin concentrations in the range of from 1 to 64 percent (by
weight, based
on the total weight of the combined resin and liquid material) may be
advantageously
utilized, with from about 10 to about 50 percent resin concentrations (on the
same basis)
being considered optimum.
Temperature is controlled during the incubation step by the thermal jacket 35
(or
other heat transfer means, such as for example a heating coil disposed in the
liquid volume
in the reservoir 34, a recirculation heater external of the reservoir, through
which liquid is
flowed from the reservoir, heated to suitable temperature in the heater unit,
and returned to
the liquid volume of the reservoir), to provide the liquid and resin mixture
with a suitable
temperature to preserve the target substance's activity. Suitable temperatures
for such
purpose may be readily determined within the skill of the art and without
undue
experimentation.
The transfer of the source liquid into the reservoir for contact with the
chromatography resin (step (1) above) and the incubation of the source liquid
with the
chromatography resin (step (2) above) can be accomplished concurrently by
simultaneously adding the source liquid to the chromatography resin reservoir
while
removing an equal volume of resin-free liquid. The controlling element in this
embodiment
of the invention is that the residence time of the source liquid in the
reservoir must be long
enough to allow for essentially complete binding of the target substance to
the
chromatography resin. This objective is readily accomplished through the
separating cross-
flow filter module 42. The permeate flow equal to the infused source liquid
volume is
removed from the loop in line 64 having valve 66 therein. The excess permeate
is sent back
to the resin reservoir in line 56 containing valve 58 therein.
The contaminants and excess liquid are separated and dialyzed away from the
chromatography resin, now bound to the target substance, by means of the
separating
26
CA 02645398 2008-11-13
WO 00/48703 PCTIUSOO/40035
cross-flow filter module 42. The resin slurry is recirculated across the cross-
flow filter
module for separation therein and retentate liquid is returned to the
reservoir. The
permeate liquid is directed to one or more of (1) a drain (by line 52
containing valve 54
therein); (2) a second reservoir, not shown, containing a subsequent resin (by
line 64
containing valve 66); (3) an independent processing step. The resin may be
concentrated
to concentrations ranging from about 0.1 to about 64 percent by volume. In one
preferred
embodiment of the invention, the resin is concentrated to about 50% resin by
volume.
The volume of wash buffer required to wash the chromatography resin depends on
the concentration of resin in suspension. For example, if the resin slurry is
100 liters of a
1% resin solution, then the volume required to wash the resin ten-fold is
1,000 liters. If the
resin slurry is 10 liters of a 10% percent resin solution, then the volume
required is 100
liters.
The time required to wash the chromatography resin also depends on the
concentration of resin in suspension, because of the effect of resin
concentration on flow
rate in the cross-flow filter module. For example, if the resin slurry is 10
liters of a 25%
resin solution, then the permeate rate might be 100 L/m2-h. If the resin
slurry is 5 liters of
a 40% resin solution, then the permeate rate might be only 10 L/m`-h.
Therefore the time
required to wash the chromatography resin slurry ten-fold with wash buffer
using a 1.0 m2
cross-flow filter module would be one hour for a 20% suspension, and a 40%
suspension
would require a wash time of five hours.
After the resin is concentrated, diafiltration is begun by addition of an
appropriate
dialysis liquid to the reservoir 34. Suitable dialysis liquids (or
"diafiltrate" or "dialysis
buffer") aid in the removal of contaminants from the resin by acting to
disrupt non-specific
binding of contaminants to the chromatography resin without causing
significant
dissociation of the bound target substance from the resin. The dialysis liquid
can be as
simple as water or as complex as multiple solvent mixtures such as 80 %
hexane, 15%
acetonitrile and 5% isopropanol solutions.
The number of dialysis buffer exchanges during this diafiltration step
preferably
ranges from 3 to 25. The preferred number of dialysis buffer exchanges is
determined
27
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
based upon the retention characteristics of the contaminants with respect to
the separating
cross-flow filter module 42 and the desired purity of the target product.
Dialysis buffer
exchange (diafiltration) to remove final traces of contaminants from the resin
slurry is
accomplished by adding makeup dialysis buffer to the slurry reservoir at the
same flow rate
as the permeate rate. This procedure can easily be automated using level
controls, load
cells, or flow meters. The extent of buffer exchange is measured in Volume
Replacements,
defined as the ratio of the cumulative volume of buffer added to the resin
slurry reservoir,
divided by the starting volume of the resin slurry. The extent of exchange or
dilution of the
original supematant with the added buffer is a geometric function. Set out
below is a table
of supematent dilution and Volume Replacements, for an illustrative embodiment
of the
invention.
Supernatant Dilution vs. Volume Replacements
Volume Replacement Concentration of Replacement Buffer in Retentate
0 0
1 50%
2 75%
3 87.5%
96.9%
7 98.7%
99.8%
28
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
The optimal separating cross-flow filter module 42 preferably has a membrane
pore
size that is 1.5 to 10 times smaller than the mean diameter of the
chromatography resin
beads. The channel height of the separating cross-flow filter module is
desirably 1.2 to 10
times larger than the mean diameter of the chromatography resin beads to
provide
satisfactory clearance and efficient hydrodynamic behavior of the filter
module. A highly
preferred design of the separating cross-flow filter module is an open channel
module with
even distribution of flow to the retentate channels. In one preferred
embodiment of the
invention, the chromatography resin beads have a mean diameter of
approximately 1 to 3
microns, the cross-flow filter has a filter element with a mean pore size of
about 0.6
microns, and the height of the retentate channel is 0.5 mm. A cross-flow
filter module
suitable for this purpose is commercially available from North Carolina SRT,
Inc. (Cary,
NC).
In one embodiment of the inventive method, the permeate from the diafiltration
step is passed through line 50 (containing drain line 64 with valve 66
therein), valve 62 and
line 60 to an additional reservoir 68 containing a second resin which effects
a second
separation of substances from the starting material.
For example, immunoglobulins to specific antigens are purified sequentially
from
plasma by the use of a series of affinity chromatography resins, each linked
with specific
viral antigens. In another illustrative example, milk proteins are separated
sequentially from whey by use of a series of specific chromatography resins,
each linked
with ligands that bind targeted proteins. These ligands can be ion exchangers,
immunoglobulins, native proteins, or any affinity ligands that bind
selectively or
preferentially to the targeted proteins and can be linked to the resins. In
yet another
illustrative example, plasma proteins are sequentially purified from whole
plasma or from
plasma fractions by use of resins linked with antibodies to the targeted
proteins.
After diafiltration to remove contaminants, the target substance is eluted and
recovered from the chromatography resin. The specific chemistry used for
elution depends
on the nature and strength of the chromatography resin-target substance
interaction. The
29
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
elution and recovery procedure is similar to the diafiltration step described
above. An
appropriate elution liquid which dissociates the target substance from the
chromatography
resin is added to the resin slurry reservoir (e.g., to reservoir 34 in line
48) at a rate equal to
the permeate rate until the desired yield is obtained. This procedure will be
extremely
useful when the chromatography resin is an ion exchange resin, because the
increase in ion
concentration can be readily monitored using a conductivity meter, and the ion
concentration will increase at a specific rate over time. In the case where
the
chromatography resin is an affinity resin, it is useful to first add a
concentrated form of the
elution buffer to the resin slurry reservoir to enhance the changeover from
diafiltration
buffer to elution buffer.
For example, in the elution of monoclonal antibodies from a Protein A resin,
the
resin slurry pH is lowered to a suitable value, e.g., on the order of pH 2.5,
by addition of a
measured volume of 1.0 M glycine buffer. The resin slun-y is then diafiltered
against ten
volumes of 0.1 M glycine buffer.
A modification of the elution step involves using a different pore size cross-
flow
filter module. For example, when eluting a plasma protein from the
chromatography resin
it would be useful to change the cross-flow membrane to a membrane which would
retain
any contaminating virus or protein-virus complexes which were not removed
during the
earlier diafiltration step 3(a).
For such modification (see Figure 6) the first cross-flow filter is 83 and the
second
filter would be 42. The resin slurry is first concentrated and diafiltered
through cross-flow
filter 83 by pump 38 through line 40 with valve 57 closed and valve 81 open.
From filter
83 the diafiltered slurry is flowed through open valve 91 and line 89 past
closed valve 46
back to reservoir 34. The permeate of this step can flow to drain or a
subsequent
purification through line 93 and open valve 99. For the elution step valves 81
and 91 are
closed and valves 57 and 46 are opened so that the eluted permeate can flow
through the
tighter filter 42 to reservoir 68 through open valve 62 and line 60. The
filter module 83 is
joined to line 93 containing valve 99 therein, as well as to line 85
containing valve 87
therein, to accommodate flow of permeate out of the filter module, or the
passage of
another mass transfer fluid (in cocurrent or countercurrent flow on the
opposite side of the
CA 02645398 2008-11-13
WO 00/48703 PCTIUSOO/40035
filter element from the liquid being filtered) to maximize mass transfer
gradient and flow
of particular species into or out of the retentate liquid.
The diafiltration and elution operations may all be carried out in the first
reservoir
34 as shown in Figure 6 and the resulting permeate comprising the target
substance may
then be passed to the second reservoir 68 for final treatment, e.g., buffering
thereof or other
treatment, with additional filtration in the cross-flow filter 82 and final
harvesting into the
harvest vessel 80. In such arrangement, some of the permeate from the first
cross-flow
filter module 83 in line 93 can be recycled through another cross-flow filter
such as a
nanofilter to minimize the amount of buffer utilized.
It will therefore be appreciated that a number of alternative apparatus
arrangements
may be constructed, arranged and operated, to carry out the separation method
of the
present invention in various embodiments thereof.
In another illustrative embodiment of the invention, a milk protein is eluted
from an
ion exchange resin to yield a protein product of enhanced purity by using a
different pore
size separating cross-flow module to effect a size separation due to the fact
that ion
exchange does not have the specificity of more expensive affinity resins.
Figure 6 as illustrated depicts a purification system that employs two cross-
flow
filter modules of different pore size that may be used for such purpose. In
the Figure 6
system, the system is correspondingly numbered with respect to Figure 5 and
the same
numbered elements are correspondingly constituted, arranged and operated.
However, as
shown in Figure 6, the system comprises another cross-flow filter module 83
that is
manifolded in parallel flow relationship to filter module 42, with filter
module 42 being in
branch line 55 containing flow control valve 57 and with the second filter
module 83 being
coupled to line 40 containing valve 81 and line 89 containing valve 91.
The second filter module 83 is also joined to lines 85 containing valve 87
therein,
and line 93, which in turn connects to line 95 containing valves 97 and 99
therein, so that
permeate from the second filter module may be selectively drained and/or
recirculated to
the reservoir 34 as shown, or alternatively so that another mass transfer
fluid can be passed
31
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
in cocurrent flow or countercurrent flow relationship with the liquid steam
being filtered,
on an opposite side of the mass transfer element(s) in the cross-flow filter
module.
In a specific embodiment of the system having the general arrangement and
layout
shown in Figure 6, the filter module 42 may contain filter (membrane)
element(s) with an
average pore size of 0.04 micron, and the filter module 83 may contain filter
(membrane)
element(s) with an average pore size of 0.6 micron. It will be recognized that
the type and
characteristics of the filter element(s) in the filter modules used in the
practice of the
present invention may be widely varied, as will be readily apparent to those
of ordinary
skill in the art, and readily implenlented with commercially available filter
elements
suitable for such purpose.
It is important to note that the eluted target substance, e.g., protein or
peptide, is
desirably captured into a reservoir under appropriate conditions, such as
temperature, pH,
and salt concentrations. It may be necessary to raise or lower the pH as well
as lower the
temperature to avoid inactivation or loss of the pure product. For example,
immunoglobulins eluted from Protein A resins should be collected in a
temperature-
controlled reservoir containing Tris buffer, pH 8 at 4 C to 10 C, which will
raise the pH
back to neutral and cool the eluate to avoid denaturing the immunoglobulins.
To ready the apparatus for subsequent use, after the target substance is
eluted and
transferred to the capture reservoir, the elution buffer is switched over to a
cleaning buffer,
followed by a storage buffer, so that the chromatography resin will be ready
for reuse.
During this step the permeate is directed to drain.
The eluted target substance, trapped in the capture reservoir, may then be
concentrated by means of an additional cross-flow filter module or other
appropriate step
such as precipitation, freeze drying, evaporation, or centrifugation to remove
the elution
buffer. In a preferred embodiment, a cross-flow filter module is employed. The
filter
medium preferably has a pore size smaller than the mean diameter of the target
substance
and larger than the ions of the elution buffer such that the target substance
can be
concentrated to an appropriate degree and the contaminating ions removed by
diafiltration.
32
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
For example, IgG purified and eluted from Protein A resin can be concentrated
and
diafiltered free of the salts of the elution buffer using a 30,000 molecular
weight
membrane. Such a cross-filtration module is commercially available from North
Carolina
SRT, Inc. (Cary, NC).
The methods described above have broad utility in purification of target
biological
substances. The source liquids can be selected from a broad range of materials
including
serum; plasma and plasma fractions; whole blood; milk; colostrum; whey;
bacterial, yeast,
fungal, insect or animal cell or tissue culture fluids and tissue homogenates.
The target.
substances can be selected from the extremely broad range of biological
substances that are
adaptable to filtration purification and that can be selectively or
preferentially bound to a
chromatography resin, including but not limited to proteins, glycoproteins,
hormones,
antigens, antibodies, clotting factors, immunoglobulins, and enzymes. The
chromatography resins are selected based on the characteristics of the target
substance,
with a wide range of well-understood ion exchange and affinity ligands being
available to
the skilled artisan and readily implemented within the skill of the art based
on the
disclosure and teachings herein.
For example, the method of the invention is useful to purify IgGs from source
liquids selected from serum, plasma, plasma fractions, whole blood, milk,
colostrum, and
whey. Clotting factors can be purified from plasma, whole blood, serum and
tissue culture.
The method of the invention has been demonstrated to provide a cost- and time-
effective route to purify IgGs from source liquids such as plasma and tissue
culture fluids.
A specific aspect of the present invention relates to the processing of a
source liquid
to recover a purified target substances therefrom, as generally described
hereinabove, but
wherein the source liquid may include biologically adverse contaminants, e.g.,
bacterial
species, viral species, antigenic species, etc. as contaminants. The invention
contemplates
the treatment of the source liquid, or other process or product stream in the
process, to
inactivate such contaminant, and render it non-adverse. By way of example, the
contaminant may comprise a viral species, e.g., HIV, hepatitis virus, etc.,
and the
inactivation of same may comprise a viricidal treatment.
33
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
The invention in a specific aspect therefore relates to a method of purifying
at least
one target substance from a source liquid containing a bioactive contaminant,
comprising
the steps of:
contacting the source liquid with a chromatography resin;
incubating the source liquid with the chromatography resin for a sufficient
contact
time to bind to the chromatography resin at least one target substance from
the
source liquid;
recirculating the chromatography resin in a cross-flow filter (e.g., one cross-
flow
filter or more than one cross-flow filter), wherein the following steps are
performed:
concentration and diafiltration of the chromatography resin;
elution of the target substance from the chromatography resin; and
separation of the target substance from the chromatography resin by
diafiltration;
recovering the target substance; and
optionally concentrating the target substance;
further comprising inactivating the bioactive contaminant during said method.
Such inactivation may involve contacting the bioactive contaminant with an
inactivating agent, e.g., as an initial step of the method, or during the
incubation of the
source liquid with the chromatography resin, during the cross-flow filtration
processing (by
addition of the inactivating agent to the target-substance containing stream
during the
filtration operation), or in any other suitable manner. The inactivating agent
may be
introduced in any suitable form, e.g., as a bound species on a chromatography
resin bead
34
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
that is otherwise functionalized for binding one or more of the target
substances, or as a
bound species on a bead having only the inactivating agent bound thereto,
wherein the
inactivating species-bound beads comprise a population component of an overall
population of beads including both inactivating species-bound beads and beads
functionalized for binding one or more of the target substances.
The inactivation agent for the viral species may be any suitable agent. As
used in
such context, the term agent is intended to be broadly construed as including
any anti-viral
molecules, complexation or capture agents which render the viral species non-
viable or
non-infective, viral transcription inhibitors, viracidal process (exposure)
conditions, etc.
Specific examples include iodine, chlorine, solvent-detergent compositions,
and ultraviolet
or other viracidal radiation exposures. Concerning the use of viral capture
agents, a viral
receptor species may be used to capture the virus in the source liquid. One
class of specific
viral capture agents includes sialic acids or nonulosaminic acids, as for
example N-
acetylneuraminic acid, N-glycolylneuraminic acid, N,O7 -diacetylneuraminic
acid, N,04-
diacetylneuraminic acid, and N,O,O-triacetylneuraminic acid. Accordingly, the
chromatographic resin may comprise microbeads with microbead-bound capture
agent
species, e.g., a microbead functionalized with a sialic acid on its surface.
In a further specific aspect, the invention relates to a process for purifying
one or
more target substances from a source liquid containing said target substances
together with
one or more viral species. Such process comprises the following steps:
CA 02645398 2008-11-13
WO 00/48703 PCTIUSOO/40035
contacting the source liquid with a viral inactivation agent for the one or
more viral
species;
concentrating the target substance(s) in the source liquid by tangential flow
filtration in a tangential flow filter comprising a membrane effective to
concentrate at least
90% by weight of the target substance(s) in such filtration;
contacting the source liquid with a chromatography resin;
incubating the source liquid with the chromatography resin for a sufficient
contact
time to bind a desired fraction of the target substance(s);
recirculating the chromatography resin in a cross-flow filter wherein the
following
steps are performed:
concentrating the chromatography resin and separating contaminants from
the chromatography-resin-bound target substance by diafiltration in a filter
comprising a
membrane effective to retain the resin and pass species that are not bound to
the resin;
eluting the target substance from the chromatography resin by contact with
an elution membrane effective to retain the resin and pass the target
substance(s);
separating the target substance froin the chromatography resin by
diafiltration;
recovering the target substance(s); and
optionally concentrating the target substance(s), e.g., by contact with a
concentration membrane effective to yield a concentrate comprising at least
90% by weight
target substance(s).
36
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
Another process variation within the scope of the invention entails a process
for
purifying one or more target substances from a source liquid containing such
target
substances. The process comprises:
contacting the source liquid with a chromatography resin;
recirculating the chromatography resin in at least one cross-flow filter
wherein the
following steps are performed:
concentrating the target substance and chromatography resin in the source
liquid by tangential flow filtration;
diafiltering the chromatography resin in a filter comprising a membrane
effective to retain the resin and pass species that are not bound to the
resin;
eluting the target substance from the chromatography resin by contact with
an elution membrane effective to retain the resin and pass the target
substance(s);
separating the target substance from the chromatography resin by diafiltration
recovering the target substance(s); and
optionally concentrating the target substance(s).
In the above-described process, the source liquid may contain one or more
pathogenic organisms, and the process may in such case further comprise the
step of
contacting the source liquid with a viral inactivation agent for such one or
more pathogenic
organisms.
In another aspect and application, the present invention relates to a method
of
manufacturing universal plasma from blood containing serological Group A
and/or Group
37
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
B antibodies, comprising contacting the blood containing serological Group A
and/or
Group B antibodies with a chromatography resin comprising corresponding Group
A
and/or Group B antigen, and recovering an antibodies-depleted blood product as
the
universal plasma.
The chromatography resin may comprise a microbead of a type as described for
example in Schwartz U.S. Patent 4,828,984 issued May 9, 1989 for "Composition,
synthesis and use of simulated cells" or Schwartz U.S. Patent 4,774,189 issued
September
27, 1988 for "Fluorescent calibration microbeads simulating stained cells,"
the disclosures
of which are hereby incorporated herein by reference in their respective
entireties.
Schwartz U.S. Patent 4,774,189 describes microbeads functionalized with
antigen species,
wherein the antigenic species are bound by primary amines on molecules thereof
to the
microbead through surface epoxy groups on the bead.
The recovery of an antibodies-depleted blood product as the universal
plasma in the above-described method may be carried out using various
concentration/elution/tangential filtration techniques of the present
invention as more
specifically described hereinabove.
The features and advantages of the invention are more fully shown with
reference
to the following non-limiting examples.
Example 1. Purification of IgG from Raw Human Plasma
38
CA 02645398 2008-11-13
WO 00/48703 PCTIUS00/40035
Using the apparatus shown schematically in Figure 5, IgG was purified from raw
human plasma by the method of the invention.
Figure 7 shows an SDS polyacrylamide gel electrophoresis (SDS-PAGE)
performed to evaluate the effectiveness of such purification. Lane 701 is a
calibration
sample containing several peptides of known molecular weight. Lanes 702 and
703 are 20
L and 40 L samples respectively of the sample after five-fold diafiltration
by cross-flow
chromatography. Lanes 704 and 705 are 20 L and 40 L samples respectively of
the
supernatant of the chromatography resin beads after diafiltration. Lanes 706
and 707 are
40 L samples of (3-mercaptoethanol digests of the materials used in Lanes 702
and 704
respectively.
Example 2. Purification of IgG from Tissue Culture Fluid
Using the apparatus shown schematically in Figure 5, IgG was purified from
tissue
culture fluid. Tissue culture fluid (20.0 L tissue culture having a
concentration of 50
g/mL IgG) was clarified by filtration using a TRIPORT filter module (North
Carolina
SRT, Inc., Cary, NC). The permeate was directed to a vessel containing a
suspension of
Orbicell -Protein A beads (Accurate Polymers, Ltd., Highland Park, IL). The
suspension
of culture fluid and beads was incubated by undergoing total recirculation
through the
TRIPORT filter module for 15 minutes at ambient temperature. The suspension
was
concentrated five-fold and then diafiltered ten-fold with 0.4 M NaCI. Elution
of the bound
IgG was performed by moving the permeate line to a quenching vessel containing
a
neutralizing buffer and changing the dialysis buffer to an acid elution
buffer. The
neutralized eluate was concentrated and then diafiltered ten-fold to remove
low molecular
weight salts formed during acid neutralization. The final yield was
approximately 100 mL
39
CA 02645398 2008-11-13
WO 00/48703 PCT/US00/40035
of purified IgG at a concentration of 10 mg/mL. The total process time was 75
minutes,
and the yield of purified IgG was 90 - 94%.
Figure 8 shows an SDS-PAGE analysis performed to evaluate the effectiveness of
the above-described purification. Lane 801 is a calibration sample containing
several
peptides of known molecular weight. Lanes 802 and 803 are 20 L and 40 L
samples
respectively of purified IgG from a first trial of the method of this example.
Lanes 804 and
805 are 20 L and 40 L samples respectively of purified IgG from a second
trial of the
method of this example. Lanes 806 and 807 are 20 L and 40 L samples
respectively of
the conditioned media used as starting material in the purification process.
Lanes 808 and
809 are 40 L samples of (3-mercaptoethanol digest of the purified IgG from
the first and
second trials respectively. Lane 810 is a 40 L sample of a R-mercaptoethanol
digest of the
conditioned media starting material.
******
While the invention has been described herein with reference to various
illustrative
features, aspects and embodiments, it will be appreciated that the invention
is susceptable
of variations, modifications and other embodiments, other than those
specifically shown
and described. The invention is therefore to be broadly interpreted and
construed as
including all such alternative variations, modifications and other embodiments
within its
spirit and scope as hereinafter claimed.
